CLAIMS

1. A compound having the formula



wherein:

R^1 is oxo, $-OR^a$, $-OC(=O)R^b$; or

R^2 is H; or

R^1 is $-OR^c$ and R^2 is $-OR^d$; or

R^1 and R^2 together form $-O(CH_2)_mO-$;

R^3 is H or C_{1-6}alkyl;

R^4 is independently selected from hydroxy, halo, C_{1-6}alkoxy, C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, carboxy, C_{1-6}alkoxy-carbonyl, carbamoyl, C_{1-6}alkylcarbamoyl, di-C_{1-6}alkylcarbamoyl, C_{1-6}alkanoyl, C_{1-6}alkanoylamino and aminosulfonyl;

R^5 is independently selected from hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, C_{1-6}alkylsulfonyl, halo, C_{1-6}alkoxy, C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, carboxy, C_{1-6}alkoxy-carbonyl, carbamoyl, C_{1-6}alkylcarbamoyl, di-C_{1-6}alkylcarbamoyl, C_{1-6}alkanoyl, C_{1-6}alkanoylamino, aminosulfonyl, and substituted C_{1-6}alkyl; or

R^4 and R^5 together form $-OCH_2O-$ or $-OC(CH_3)_2O-$;

R^6 is selected from hydrogen, hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, C_{1-6}alkylsulfonyl, halo, C_{1-6}alkoxy, C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, carboxy, C_{1-6}alkoxy-carbonyl, carbamoyl, C_{1-6}alkylcarbamoyl, di-C_{1-6}alkylcarbamoyl, C_{1-6}alkanoyl, C_{1-6}alkanoylamino, aminosulfonyl, and substituted C_{1-6}alkyl

R^7 is substituted phenyl;

R^8 is selected from hydrogen, hydroxy, C_{1-6}alkoxy, C_{1-6}alkanoyloxy, C_{1-6}alkanoyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkanoylamino, C_{1-6}alkyl, carbamoyl, C_{1-6}alkylcarbamoyl, and bis(C_{1-6}alkyl)carbamoyl;

R^a is hydrogen or C_{1-6}alkyl;

R^b is C_{1-6}alkyl, aryl or arylC_{1-6}alkyl;

R^c and R^d are independently selected from C_{1-6}alkyl;

m is 2, 3, or 4; and

X^1 and X^2 are independently H or halogen, wherein at least one of X^1 and X^2 are halogen; and

any pharmaceutically-acceptable salt thereof.

2. A compound according to Claim 1 wherein:

R^1 is oxo, -OR^a, or -$OC(=O)R^b$; or

R^1 is -OR^c and R^2 is -OR^d.

3. A compound according to Claim 1 wherein:

R^1 is



; and

R^2 is H.

4. A compound according to Claim 3 wherein:

R^7 is phenyl substituted in the ortho position by a substituent selected from C_{1-6}alkylthio, C_{1-6}alkylsulfinyl, C_{1-6}alkylsulfonyl, trifluoromethylthio, trifluoromethylsulfinyl, C_{1-6}alkanesulfonamido, C_{1-6}alkanoyl, C_{1-6}alkoxy-carbonyl, succinamido, carbamoyl, C_{1-6}alkylcarbamoyl, di-C_{1-6}alkylcarbamoyl, C_{1-6}alkoxy-C_{1-6}alkylcarbamoyl, C_{1-6}alkanoylamino, ureido, C_{1-6}ureido, di-C_{1-6}alkylureido, amino, C_{1-6}alkylamino and di-C_{1-6}alkylamino; and substituted in the para position by a substituent selected from

hydrogen, methyl, methoxy, acetyl, acetylamino, methoxycarbonyl, methanesulfonylamino, methyl-sulfinyl, methylsulfonyl, trifluoromethyl, trifluoromethylthio, trifluoromethylsulfinyl, bromo, fluoro, chloro, hydroxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl-methylureido and dimethylureido; and

R^8 is selected from hydrogen, hydroxy, methoxycarbonyl, methylcarbamoyl and dimethylcarbamoyl.

5. A compound according to Claim 4 wherein:

R^7 is methylsulfinyl, methylsulfonyl, methylureido, dimethylureido, amino, methylamino or dimethylamino;

R^8 is hydroxy or hydrogen; and

R^9 is hydrogen, C_{1-6}alkoxy, halo, C_{1-6}alkylsulfinyl, or carboxy.

6. A compound according to Claim 5 wherein:

R^7 is



;

R^8 is hydrogen; and

R^9 is hydrogen, methoxy or fluoro.

7. A compound according to any of Claims 2, 3, 4, or 6 wherein:

R^3 is hydrogen, methyl or ethyl;

R^4 is C_{1-4}alkoxy, C_{1-4}alkyl, halogen, haloC_{1-2}alkoxy, haloC_{1-4}alkyl, $-CH=CHCH_3$, $-S(O)_nCH_3$, or $-OS(O)_2CH_3$;

R^5 is cyano, nitrogen, hydrogen or halogen;

R^6 is hydrogen, methoxy, cyano or nitro; and

n is 0, 1 or 2.

8. A compound according to Claim 7 wherein:

R^3 is hydrogen, methyl or ethyl;

R^4 is methyl, ethyl, methoxy, ethoxy, hydroxy or fluoro;

R^5 is cyano or nitro; and

R^6 is hydrogen.

9. A process for preparing a compound according to Claim 3 which process comprises the step of:

reacting a compound of the formula (III) with a compound of the formula (IV) under reductive amination conditions:



(IV)

wherein R^3 through R^8, X^1 and X^2 are as in Claim 3; and L and L' are groups such that reductive amination of the compounds of the formulae (III) and (IV) forms a N-C bond; or

reacting a compound of the formula (V) with a compound of the formula (VI):



(V)



(VI)

wherein R^3 through R^8, X^1 and X^2 are as defined in Claim 3; and L" is a leaving group.

10. A pharmaceutical composition comprising a compound according to any one of Claims 1 through 8.

11. A method of treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, anxiety, emesis, Huntington's disease, psychoses including depression, hypertension, migraine, bladder hypermotility, or urticaria comprising administering an effective amount of an NK$_1$ antagonist according to any one of Claims 1 through 8.